Don't Expect to See a Lot More PCSK9 Inhibitor Rxs

May 2017

You'll hear buzz about using the PCSK9 inhibitors, Repatha (evolocumab) or Praluent (alirocumab), in patients with CV disease.

These injectable meds lower LDL cholesterol by about 60%...but we've been waiting to see if they improve CV outcomes.

Now evidence suggests that adding Repatha to a statin in patients with CV disease and other risks (diabetes, etc) prevents one more CV event for every 74 patients treated for about 2 years.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get quote

Cardiology Tell Patients Not to Rely on Fish Oil Supplements to Reduce CV Risk
Pregnancy Watch for Oral Antibiotics That Should Be Avoided During Pregnancy
Insulin Think of Fiasp as a Faster-Acting Form of NovoRapid
Oral Health Avoid Antibiotic Prophylaxis for Dental Patients With Prosthetic Joints
Overactive Bladder Mictoryl Is Similar to Other Antimuscarinics for Overactive Bladder
Back Pain Don't Rely on Acetaminophen for Chronic Low Back Pain
Rheumatology Expect Kevzara to Be Used After TNF Blockers
Antithrombotics Expect Anticoagulant Use After Intracranial Hemorrhage in Some A Fib Patients
Cholesterol Don't Expect to See a Lot More PCSK9 Inhibitor Rxs
Vaccines Watch for Confusing Abbreviations With Vaccines
HIV & AIDS Don't Give Partial HIV Regimens When Patients Are Hospitalized

Don't Expect to See a Lot More PCSK9 Inhibitor Rxs

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents